Desiree E Sanchez, Alireza Ghoreifi, Lorenzo Storino Ramacciotti, Jie Cai, Marissa Maas, Abhishek Venkat, Randall Lee, Andre Luis Abreu, Giovanni E Cacciamani, Leo Doumanian, Inderbir Gill, Andrew Liu-Chen, Mike Nguyen, Rene Sotelo, Mihir M Desai
{"title":"良性前列腺增生患者既往手术水消融的安全性和可行性。","authors":"Desiree E Sanchez, Alireza Ghoreifi, Lorenzo Storino Ramacciotti, Jie Cai, Marissa Maas, Abhishek Venkat, Randall Lee, Andre Luis Abreu, Giovanni E Cacciamani, Leo Doumanian, Inderbir Gill, Andrew Liu-Chen, Mike Nguyen, Rene Sotelo, Mihir M Desai","doi":"10.1089/end.2024.0370","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> Aquablation for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) has been adopted to treat a wide range of prostate anatomies including glands up to 150 cc. Patients with recurrence of LUTS after previous BPH procedure often present with variant anatomy, and a paucity of literature exists on the optimal treatment modality for these patients. Herein, we evaluate the safety and feasibility of aquablation in patients with previous BPH surgical history. <b><i>Patients and Methods:</i></b> A prospectively managed single institution database of aquablation patients with BPH/LUTS was queried from August 2020 to December 2022 for patients who failed previous BPH procedures. Patients were divided into two groups: those with and without previous BPH procedure. Primary outcomes were intraoperative and 90-day complications. Secondary outcomes included operative time (OT), number of Aquabeam passes, estimated blood loss, hospital length of stay, and catheter duration. Outcomes were assessed using chi-squared, Wilcoxon rank sum tests, and logistic regression. <b><i>Results:</i></b> A total of 200 patients with BPH/LUTS were treated with aquablation. We identified 26 patients with a history of previous BPH procedures. Patients who underwent previous BPH procedures had smaller prostate volumes (60 cc) compared with treatment-naïve (88 cc) patients, <i>p</i> = 0.016. There was no difference in perioperative and 90-day complications (29% for treatment-naïve <i>vs</i> 17% in the retreatment group, <i>p</i> = 0.32). Most secondary outcomes were the same including OT, but the retreatment group had fewer Aquabeam passes (2 [1-2] <i>vs</i> 2 [2-2] treatment-naïve, <i>p</i> = 0.037) and more additional procedures at follow-up (30% <i>vs</i> 8.3% treatment-naïve, <i>p</i> = 0.005). <b><i>Conclusion:</i></b> Patients with previous BPH interventions remain excellent candidates for aquablation, with similar perioperative and 90-day postoperative outcomes compared with intervention-naïve patients. Aquablation demonstrates efficient tissue ablation without the risk of increased injury or significant blood loss after prior failed BPH procedures.</p>","PeriodicalId":15723,"journal":{"name":"Journal of endourology","volume":" ","pages":"50-55"},"PeriodicalIF":2.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Safety and Feasibility of Aquablation in Patients with Previous Surgery for Benign Prostatic Hyperplasia.\",\"authors\":\"Desiree E Sanchez, Alireza Ghoreifi, Lorenzo Storino Ramacciotti, Jie Cai, Marissa Maas, Abhishek Venkat, Randall Lee, Andre Luis Abreu, Giovanni E Cacciamani, Leo Doumanian, Inderbir Gill, Andrew Liu-Chen, Mike Nguyen, Rene Sotelo, Mihir M Desai\",\"doi\":\"10.1089/end.2024.0370\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Objective:</i></b> Aquablation for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) has been adopted to treat a wide range of prostate anatomies including glands up to 150 cc. Patients with recurrence of LUTS after previous BPH procedure often present with variant anatomy, and a paucity of literature exists on the optimal treatment modality for these patients. Herein, we evaluate the safety and feasibility of aquablation in patients with previous BPH surgical history. <b><i>Patients and Methods:</i></b> A prospectively managed single institution database of aquablation patients with BPH/LUTS was queried from August 2020 to December 2022 for patients who failed previous BPH procedures. Patients were divided into two groups: those with and without previous BPH procedure. Primary outcomes were intraoperative and 90-day complications. Secondary outcomes included operative time (OT), number of Aquabeam passes, estimated blood loss, hospital length of stay, and catheter duration. Outcomes were assessed using chi-squared, Wilcoxon rank sum tests, and logistic regression. <b><i>Results:</i></b> A total of 200 patients with BPH/LUTS were treated with aquablation. We identified 26 patients with a history of previous BPH procedures. Patients who underwent previous BPH procedures had smaller prostate volumes (60 cc) compared with treatment-naïve (88 cc) patients, <i>p</i> = 0.016. There was no difference in perioperative and 90-day complications (29% for treatment-naïve <i>vs</i> 17% in the retreatment group, <i>p</i> = 0.32). Most secondary outcomes were the same including OT, but the retreatment group had fewer Aquabeam passes (2 [1-2] <i>vs</i> 2 [2-2] treatment-naïve, <i>p</i> = 0.037) and more additional procedures at follow-up (30% <i>vs</i> 8.3% treatment-naïve, <i>p</i> = 0.005). <b><i>Conclusion:</i></b> Patients with previous BPH interventions remain excellent candidates for aquablation, with similar perioperative and 90-day postoperative outcomes compared with intervention-naïve patients. Aquablation demonstrates efficient tissue ablation without the risk of increased injury or significant blood loss after prior failed BPH procedures.</p>\",\"PeriodicalId\":15723,\"journal\":{\"name\":\"Journal of endourology\",\"volume\":\" \",\"pages\":\"50-55\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of endourology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/end.2024.0370\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of endourology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/end.2024.0370","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:水消融治疗良性前列腺增生(BPH)继发的下尿路症状(LUTS)已被广泛用于治疗前列腺解剖结构,包括高达150cc的腺体。先前BPH手术后复发的下尿路症状患者通常具有不同的解剖结构,并且缺乏关于这些患者的最佳治疗方式的文献。在此,我们评估了有BPH手术史的患者水中消融的安全性和可行性。患者和方法:对2020年8月至2022年12月期间BPH/LUTS水消融患者的前瞻性管理单一机构数据库进行查询,其中包括先前BPH手术失败的患者。患者分为两组:有和没有先前的BPH手术。主要结局为术中并发症和90天并发症。次要结果包括手术时间(OT)、Aquabeam通过次数、估计失血量、住院时间和导管时间。使用卡方检验、Wilcoxon秩和检验和逻辑回归评估结果。结果:共200例BPH/LUTS患者接受了水消融治疗。我们确定了26例既往有BPH手术史的患者。与treatment-naïve (88 cc)患者相比,先前接受过BPH手术的患者前列腺体积(60 cc)较小,p = 0.016。围手术期和90天并发症无差异(treatment-naïve组为29%,再治疗组为17%,p = 0.32)。包括OT在内的大多数次要结果相同,但再治疗组的Aquabeam通过次数较少(2次[1-2]vs 2次[2-2]treatment-naïve, p = 0.037),随访时更多的附加程序(30% vs 8.3% treatment-naïve, p = 0.005)。结论:与intervention-naïve患者相比,既往BPH干预患者的围手术期和术后90天预后相似,仍然是水消融的优秀候选人。在先前失败的BPH手术后,水消融证明有效的组织消融没有增加损伤或显著失血的风险。
The Safety and Feasibility of Aquablation in Patients with Previous Surgery for Benign Prostatic Hyperplasia.
Objective: Aquablation for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) has been adopted to treat a wide range of prostate anatomies including glands up to 150 cc. Patients with recurrence of LUTS after previous BPH procedure often present with variant anatomy, and a paucity of literature exists on the optimal treatment modality for these patients. Herein, we evaluate the safety and feasibility of aquablation in patients with previous BPH surgical history. Patients and Methods: A prospectively managed single institution database of aquablation patients with BPH/LUTS was queried from August 2020 to December 2022 for patients who failed previous BPH procedures. Patients were divided into two groups: those with and without previous BPH procedure. Primary outcomes were intraoperative and 90-day complications. Secondary outcomes included operative time (OT), number of Aquabeam passes, estimated blood loss, hospital length of stay, and catheter duration. Outcomes were assessed using chi-squared, Wilcoxon rank sum tests, and logistic regression. Results: A total of 200 patients with BPH/LUTS were treated with aquablation. We identified 26 patients with a history of previous BPH procedures. Patients who underwent previous BPH procedures had smaller prostate volumes (60 cc) compared with treatment-naïve (88 cc) patients, p = 0.016. There was no difference in perioperative and 90-day complications (29% for treatment-naïve vs 17% in the retreatment group, p = 0.32). Most secondary outcomes were the same including OT, but the retreatment group had fewer Aquabeam passes (2 [1-2] vs 2 [2-2] treatment-naïve, p = 0.037) and more additional procedures at follow-up (30% vs 8.3% treatment-naïve, p = 0.005). Conclusion: Patients with previous BPH interventions remain excellent candidates for aquablation, with similar perioperative and 90-day postoperative outcomes compared with intervention-naïve patients. Aquablation demonstrates efficient tissue ablation without the risk of increased injury or significant blood loss after prior failed BPH procedures.
期刊介绍:
Journal of Endourology, JE Case Reports, and Videourology are the leading peer-reviewed journal, case reports publication, and innovative videojournal companion covering all aspects of minimally invasive urology research, applications, and clinical outcomes.
The leading journal of minimally invasive urology for over 30 years, Journal of Endourology is the essential publication for practicing surgeons who want to keep up with the latest surgical technologies in endoscopic, laparoscopic, robotic, and image-guided procedures as they apply to benign and malignant diseases of the genitourinary tract. This flagship journal includes the companion videojournal Videourology™ with every subscription. While Journal of Endourology remains focused on publishing rigorously peer reviewed articles, Videourology accepts original videos containing material that has not been reported elsewhere, except in the form of an abstract or a conference presentation.
Journal of Endourology coverage includes:
The latest laparoscopic, robotic, endoscopic, and image-guided techniques for treating both benign and malignant conditions
Pioneering research articles
Controversial cases in endourology
Techniques in endourology with accompanying videos
Reviews and epochs in endourology
Endourology survey section of endourology relevant manuscripts published in other journals.